Unveiling the spectrum of Respiratory Syncytial Virus disease in Adults: from Community to Hospital
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Respiratory syncytial virus can cause severe disease in the older adult population. Three vaccines for RSV are currently market approved but the risk of RSV-hospitalization in (older) adults from a community level remains elusive. We aimed to estimate the risk of RSV-hospitalization and characterize the patients that end up in hospital.
Methods
We manually analyzed records of adults aged ≥20 with RSV-infection between 2022-2024 in three hospitals in the Netherlands. These hospitals implemented routine RSV-testing at emergency departments. Using population-based data in combination with the in-hospital data, we estimated the population risk of RSV-hospitalization. Hospital records were analyzed to characterize the role RSV played in their course of disease.
Results
We analyzed 709 RSV cases of whom 503 (70.9%) were hospitalized. 526 patients were ≥60, and 183 were <60 years of age. The population risk of RSV-hospitalization was 0.006-0.02% for patients aged 20-59 years and 0.04-0.24% for those ≥60. The highest risks were seen in older patients with congestive heart disease (0.14-5.0%) and COPD (0.17-1.76%). RSV caused clinically relevant infection in 88% of hospitalized cases but was only mentioned using specific ICD-codes in 4.4%. Comorbidity was prevalent (88.5%) and exacerbation of underlying disease caused of 46.3% of RSV-related hospital admissions. ICU admittance was 11.2% and in-hospital mortality was 8.1%.
Conclusion
The risk of RSV-hospitalization from the community is low but is increased substantially in those with underlying disease. RSV is often clinically relevant in hospitalized patients by causing exacerbation of underlying disease but is infrequently mentioned in specific ICD-codes.
